Jonathan Zalevsky: Okay and hey Jerry. This is JZ. So, in response to your first question, the study design is being finalized now and where we still have to wait for the feedback that we get from the health authorities. But I can give you a little bit of color. We are planning to enroll approximately 280 patients. We will have multiple dose regimens that we will evaluate in the induction phase. And then in the maintenance phase, we will also be looking at very infrequent dosing regimens. And the purpose of this design is really to springboard from the things that we learned in the Phase 1b study. So there, we saw that strong and long durability of effect which we believe in the maintenance arm can allow us to access very, very low-frequency dosing, which would be highly differentiating.
I guess all of the other agents in the class that require either a twice monthly or monthly that kind of a dosing regimen. And as we get closer to later this year, closer to kicking off the study, we will give another update where we will unveil the design of the study, some of the key endpoints that we are measuring and all of the additional features. So, please stay tuned for that. It will be coming up soon.
Jerry Gong: Super helpful. Thanks for the answers.
Operator: Thank you. Our next question will come from Jessica Fye from JPMorgan. Your line is open.
Unidentified Analyst: Hey. Good afternoon. This is JL for Jess. So, a couple of questions from us. First of all, for your kind of strategic decision to partner on 255, just wondering is this something new after you kind of regain the full right of REZPEG, or was it always on the table for 255? And then on your cash runway, is there any extra color that you could kind of can set right for us, for example, that your current cash run rate to at least mid-2023 kind of budget in completing the Phase 2b study for REZPEG? And does it also kind of budget in your 255 study, right, with cell therapy in Phase 2, I believe that’s currently active? And I think you kind of announced some new programs just now and how much cash runway have you budgeted for those preclinical studies, assuming some of them can move into the clinic? Thank you very much.
Howard Robin: Okay. Good. Very good questions. Look, we were – look, when we have been working – as an immunology company, an immunology company, of course 255 was an important component of our portfolio, and I still think NKTR-255, IL-15 has an important role in immuno-oncology. That said, we need to focus and we need to focus where the opportunities are the largest and the opportunities to have a novel mechanism are available to us, and that’s REZPEG. So, will we keep working on 255, yes. But I do want – I do think we have changed our mind at this point over the past years and have decided that as an immunology company, we would like to find a strategic partner for NKTR-255. And that’s to allow us to fully exploit our skills in immunology.
Now, to the second part of your question, our cash runway through at least ‘26 includes the full cost of a 2b study in atopic dermatitis. That full cost is in there, it’s approximately $60 million. That is fully accounted for in there, as is the cost of continuing the NKTR-255 studies to gain a partnership as well as the IND filing for those two programs. So, that’s all in the cash runway through 2026. If we do any other deals or any other opportunities in there that will just add – as Sandra said earlier, that will just add to the length of our cash runway. I hope that answers it.
Operator: Thank you. And our next question will come from Greg Harrison from Bank of America. Your line is open.
